China's Tencent Holdings is tying up with a technology firm from the United Kingdom called Medopad Ltd to use artificial intelligence for the purpose of improving Parkinson's disease treatment. The company is collaborating with Medopad to develop a system to remotely monitor patients with severe movement disorder. The company said that the basic goal is to allow doctors to set drug doses and modify care without patients having to go to the hospital. Healthcare is increasingly "not only about what happens in the clinic, but what happens in the real world", Wei Fan, Tencent's executive director for medical AI research said. "The reason we want to work with Medopad is they're experts in monitoring patients."

Chinese tech and entertainment-oriented conglomerate Tencent Holdings is collaborating with the London-based health app developer Babylon Health, founded in 2013, to introduce medical chatbot AI capabilities into their solutions. While the press release from Babylon Health does not go into detail about the target scenario, Financial Times writer Aliya Ram suggests that the technology will directly go into Tencent's social messaging platform WeChat. No financial details on the deal have been disclosed. WeChat itself could be considered a hybrid of Facebook, WhatsApp, and Twitter from a functional point of view. Even though they are primarily used only in China, with their 1 billion monthly active users they can be considered as one of the world's most popular communication platforms.